Literature DB >> 18473176

A glass of water immediately increases gastric pH in healthy subjects.

George Karamanolis1, Ioanna Theofanidou, Marina Yiasemidou, Evangelos Giannoulis, Konstantinos Triantafyllou, Spiros D Ladas.   

Abstract

UNLABELLED: Onset of action of antisecretory agents is of pivotal importance for patients with gastroesophageal reflux disease (GERD) treated "on-demand." AIM: To study the acute effect of acid-inhibiting drugs and water administration on gastric pH.
METHOD: A cross-over study was performed in 12 H. pylori (-), healthy subjects (6 men; mean age: 26 years). A single oral dose of the following agents was received with a wash-out period between each study: a glass of water (200 ml), antacid, ranitidine, omeprazole, esomeprazole, and rabeprazole. Gastric pH was recorded for 6 h after drug intake.
RESULTS: Water increased gastric pH >4 in 10/12 subjects after 1 min. The time (median) needed to pH >4 was for: antacid 2 min, ranitidine 50 min, omeprazole 171 min, esomeprazole 151 min, and rabeprazole 175 min. Gastric pH >4 lasted for 3 min after water and for 12 min after antacids; it remained >4 until the end of recording in: 4/12 subjects with ranitidine, 11/12 with rabeprazole, and all with omeprazole and esomeprazole.
CONCLUSION: Water and antacid immediately increased gastric pH, while PPIs showed a delayed but prolonged effect compared to ranitidine.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18473176     DOI: 10.1007/s10620-008-0301-3

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  16 in total

Review 1.  New-generation proton pump inhibitors: overcoming the limitations of early-generation agents.

Authors:  M Robinson
Journal:  Eur J Gastroenterol Hepatol       Date:  2001-05       Impact factor: 2.566

2.  Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group.

Authors:  R Carlsson; J Dent; R Watts; S Riley; R Sheikh; J Hatlebakk; K Haug; G de Groot; A van Oudvorst; A Dalväg; O Junghard; I Wiklund
Journal:  Eur J Gastroenterol Hepatol       Date:  1998-02       Impact factor: 2.566

Review 3.  Nonerosive reflux disease--current concepts and dilemmas.

Authors:  R Fass; M B Fennerty; N Vakil
Journal:  Am J Gastroenterol       Date:  2001-02       Impact factor: 10.864

4.  Post-prandial ranitidine is superior to post-prandial omeprazole in control of gastric acidity in healthy volunteers.

Authors:  R M Khoury; P O Katz; D O Castell
Journal:  Aliment Pharmacol Ther       Date:  1999-09       Impact factor: 8.171

5.  Comparison of acid inhibition by either oral high-dose ranitidine or omeprazole.

Authors:  S Hurlimann; B Abbühl; W Inauen; F Halter
Journal:  Aliment Pharmacol Ther       Date:  1994-04       Impact factor: 8.171

6.  Appropriate acid suppression for the management of gastro-oesophageal reflux disease.

Authors:  N J Bell; D Burget; C W Howden; J Wilkinson; R H Hunt
Journal:  Digestion       Date:  1992       Impact factor: 3.216

7.  Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors.

Authors:  D Pantoflickova; G Dorta; M Ravic; P Jornod; A L Blum
Journal:  Aliment Pharmacol Ther       Date:  2003-06-15       Impact factor: 8.171

8.  Prognostic factors for relapse and maintenance treatment with cisapride in gastro-oesophageal reflux disease.

Authors:  G N Tytgat; A L Blum; M Verlinden
Journal:  Aliment Pharmacol Ther       Date:  1995-06       Impact factor: 8.171

9.  Who is using chronic acid suppression therapy and why?

Authors:  Brian C Jacobson; Timothy G Ferris; Tara L Shea; Emmanuel M Mahlis; Thomas H Lee; Timothy C Wang
Journal:  Am J Gastroenterol       Date:  2003-01       Impact factor: 10.864

10.  Intragastric pH after oral administration of single doses of ranitidine effervescent tablets, omeprazole capsules and famotidine fast-dissolving tablets to fasting healthy volunteers.

Authors:  H Hedenström; C Alm; M Kraft; A Grahnén
Journal:  Aliment Pharmacol Ther       Date:  1997-12       Impact factor: 8.171

View more
  8 in total

1.  Early effect of oral administration of omeprazole with mosapride as compared with those of omeprazole alone on the intragastric pH.

Authors:  Hiroshi Iida; Masahiko Inamori; Tetsuro Fujii; Yusuke Sekino; Hiroki Endo; Kunihiro Hosono; Takashi Nonaka; Tomoko Koide; Hirokazu Takahashi; Masato Yoneda; Ayumu Goto; Yasunobu Abe; Noritoshi Kobayashi; Hiroyuki Kirikoshi; Kensuke Kubota; Satoru Saito; Eiji Gotoh; Shin Maeda; Atsushi Nakajima
Journal:  BMC Gastroenterol       Date:  2012-03-26       Impact factor: 3.067

2.  Hypothesis of zinc ascorbate as best zinc ionophore for raising antiviral resistance against Covid-19.

Authors:  Valentino Cingolani
Journal:  J Med Virol       Date:  2021-05-28       Impact factor: 20.693

3.  Challenges of correlating pH change with relief of clinical symptoms in gastro esophageal reflux disease: a phase III, randomized study of Zegerid versus Losec.

Authors:  Dave Walker; Richard Ng Kwet Shing; Deborah Jones; Hans-Jurgen Gruss; Jarosław Reguła
Journal:  PLoS One       Date:  2015-02-23       Impact factor: 3.240

4.  Early effect on intragastric pH of oral administration of rabeprazole with mosapride compared with rabeprazole alone.

Authors:  Hiroshi Iida; Megumi Kaai; Yumi Inoh; Kenji Kanoshima; Kanji Ohkuma; Takashi Nonaka; Koji Fujita; Tomonori Ida; Akihiko Kusakabe; Shin Maeda; Atsushi Nakajima; Masahiko Inamori
Journal:  Ann Gastroenterol       Date:  2017-05-19

Review 5.  In Vitro Methodologies for Evaluating Colon-Targeted Pharmaceutical Products and Industry Perspectives for Their Applications.

Authors:  Mauricio A García; Felipe Varum; Jozef Al-Gousous; Michael Hofmann; Susanne Page; Peter Langguth
Journal:  Pharmaceutics       Date:  2022-01-26       Impact factor: 6.321

6.  Early effects of oral administration of lafutidine with mosapride compared with lafutidine alone on intragastric pH values.

Authors:  Hiroshi Iida; Masahiko Inamori; Yuichi Nozaki; Hiroki Endo; Kunihiro Hosono; Tomoyuki Akiyama; Yasunari Sakamoto; Hirokazu Takahashi; Tomoko Koide; Chikako Tokoro; Yasunobu Abe; Atsushi Nakajima
Journal:  BMC Gastroenterol       Date:  2009-07-09       Impact factor: 3.067

7.  In-Vitro and In-Vivo Evaluation of Velpatasvir- Loaded Mesoporous Silica Scaffolds. A Prospective Carrier for Drug Bioavailability Enhancement.

Authors:  Yasir Mehmood; Ikram Ullah Khan; Yasser Shahzad; Rizwan Ullah Khan; Muhammad Shahid Iqbal; Haseeb Ahmad Khan; Ikrima Khalid; Abid Mehmood Yousaf; Syed Haroon Khalid; Sajid Asghar; Muhammad Asif; Talib Hussain; Shefaat Ullah Shah
Journal:  Pharmaceutics       Date:  2020-03-28       Impact factor: 6.321

8.  SARS-CoV-2 Survival in Common Non-Alcoholic and Alcoholic Beverages.

Authors:  Mo Jia; Jonathan D Joyce; Andrea S Bertke
Journal:  Foods       Date:  2022-03-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.